21.11.2019 Vivoryon Therapeutics AG  DE0007921835

DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019


 

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous
Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019
21.11.2019 / 07:00
The issuer is solely responsible for the content of this announcement.


Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019


HALLE (SAALE), Germany, 21 November 2019 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its third quarter financial results and a business update for the period ended September 30, 2019 on Thursday, November 28, 2019, in the form of an interim management report.

###

For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Email: contact@vivoryon.com

Trophic Communications
Gretchen Schweitzer / Joanne Tudorica
Tel: +49 (0)172 861 8540 / +49 (0)176 2103 7191
Email: trophic@vivoryon.com

MC Services AG
Anne Hennecke / Susanne Kutter
Tel: +49 (0) 211 529 252 27
Email: vivoryon@mc-services.eu

About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, PQ912, in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. (www.vivoryon.com)

Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.



21.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vivoryon Therapeutics AG
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: contact@vivoryon.com
Internet: www.vivoryon.com
ISIN: DE0007921835
WKN: 792183
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 917437

 
End of News DGAP News Service

917437  21.11.2019 

fncls.ssp?fn=show_t_gif&application_id=917437&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBITDA1,2 -10,56 -9,65 -11,27 -13,39 -13,67 -9,86 -7,68 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBIT1,4 -10,56 -9,65 -11,27 -13,39 -13,77 -9,96 -7,70 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Jahresüberschuss1 -18,72 -9,93 -11,44 -13,51 -13,89 -8,01 -7,74 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Cashflow1,7 -12,04 -8,53 -10,59 -12,15 -13,26 -12,12 -6,99 0,00
Ergebnis je Aktie8 -0,47 -0,38 -2,35 -1.97 -1,82 -0,98 -0,94 -0,55
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Vivoryon Therapeutics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
792183 5,070 101,28
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,000 -4,37
KBV KCV KUV EV/EBITDA
2,22 - 1.687,93 -12,936
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
Hauptversammlung
0,00 0,00 0,00 29.05.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
14.05.2020 27.08.2020 28.11.2019 26.03.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-9,79% 0,00% 0,00% 0,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Vivoryon Therapeutics AG  ISIN: DE0007921835 können Sie bei DGAP abrufen

Biotechnologie , 792183 , VVY , XETR:PB9